Treatment of symptomatic benign prostatic hyperplasia

Details Treatment of symptomatic benign prostatic hyperplasia Treatment of symptomatic benign prostatic hyperplasia

1993-04-30

1995-10-31

Goldberg, Jerome D.

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

Elemental iodine or iodine compound

A61K 3336

Patent

active

054627532

ABSTRACT:
Use of potassium iodide, administered orally, in an average daily dosage of 0.10 to 0.40 milligrams for the treatment of symptomatic Benign Prostatic Hyperplasia. The potassium iodide preferably is used in the form of a saturated aqueous solution of potassium iodide.

REFERENCES:
patent: 4946688 (1990-08-01), Fahim
patent: 5102912 (1992-04-01), Streber

Affiliated with

Also associated with

Rating

Treatment of symptomatic benign prostatic hyperplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of symptomatic benign prostatic hyperplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of symptomatic benign prostatic hyperplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1770697